Researchers have demonstrated that restoring levels of a key brain energy molecule can reverse advanced Alzheimer's disease in mouse models, repairing damage and restoring cognitive function. The study, published on December 22, challenges the long-held view that the condition is irreversible. Findings from human brain tissue support the approach's potential relevance to patients.
For over a century, Alzheimer's disease has been regarded as a progressive and irreversible condition, with research efforts primarily aimed at prevention or slowing its advance. A new study led by Kalyani Chaubey, PhD, from the Pieper Laboratory at University Hospitals, along with colleagues from Case Western Reserve University and the Louis Stokes Cleveland VA Medical Center, questions this paradigm.
Published on December 22 in Cell Reports Medicine, the research examined human Alzheimer's brain tissue and two mouse models engineered with genetic mutations mimicking human amyloid and tau abnormalities. These models exhibited hallmarks of the disease, including blood-brain barrier breakdown, inflammation, neuronal damage, and cognitive deficits.
The team identified severely depleted levels of NAD+, a vital cellular energy molecule that declines with age but drops more dramatically in Alzheimer's-affected brains. Using the compound P7C3-A20, developed in the Pieper lab, they restored NAD+ balance. In mice treated before symptoms, the disease was prevented. Strikingly, in advanced cases, treatment led to repair of brain pathology, full cognitive recovery, and normalization of the biomarker phosphorylated tau 217 in blood tests.
"We were very excited and encouraged by our results," said senior author Andrew A. Pieper, MD, PhD, director of the Brain Health Medicines Center at University Hospitals. "Restoring the brain's energy balance achieved pathological and functional recovery in both lines of mice with advanced Alzheimer's."
Dr. Pieper emphasized that this differs from over-the-counter NAD+ precursors, which can raise levels excessively and risk promoting cancer. Instead, P7C3-A20 maintains balance under stress. "The key takeaway is a message of hope -- the effects of Alzheimer's disease may not be inevitably permanent," he added.
The approach builds on prior work showing NAD+ restoration aids recovery from traumatic brain injury. Commercialization is underway through Glengary Brain Health, co-founded by Dr. Pieper. Future steps include pinpointing key energy aspects, complementary therapies, and clinical trials to test translation to humans, potentially extending to other neurodegenerative conditions.
